The transforming growth factor (TGF)--inducible integrin ␣v6 is preferentially expressed at sites of epithelial remodeling and has been shown to bind and activate latent precursor TGF-. Herein , we show that ␣v6 is overexpressed in human kidney epithelium in membranous glomerulonephritis , diabetes mellitus , IgA nephropathy , Goodpasture's syndrome , and Alport syndrome renal epithelium. To assess the potential regulatory role of ␣v6 in renal disease , we studied the effects of functionblocking ␣v6 monoclonal antibodies (mAbs) and genetic ablation of the 6 subunit on kidney fibrosis in Col4A3 ؊/؊ mice , a mouse model of Alport syndrome. Expression of ␣v6 in Alport mouse kidneys was observed primarily in cortical tubular epithelial cells and in correlation with the progression of fibrosis. Treatment with ␣v6-blocking mAbs inhibited accumulation of activated fibroblasts and deposition of interstitial collagen matrix. Similar inhibition of renal fibrosis was observed in 6-deficient Alport mice. Transcript profiling of kidney tissues showed that ␣v6-blocking mAbs significantly inhibited disease-associated changes in expression of fibrotic and inflammatory mediators. Similar patterns of transcript modulation were produced with recombinant soluble TGF- RII treatment , suggesting shared regulatory functions of ␣v6 and TGF-. These findings demonstrate that ␣v6 can contribute to the regulation of renal fibrosis and suggest this integrin as a potential therapeutic target.